Haisco Pharmaceutical Group Co Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Haisco Pharmaceutical Group Co Ltd with three other
companies in this sector in China:
SSY Group Ltd
sales of 3.53 billion Chinese Renmimbi [US$498.67 million]
of which 96%
was Intravenous Infusion Solution and Others),
Jilin Aodong Medicine Industry (Group) Co., Ltd.
(3.32 billion Chinese Renmimbi [US$469.35 million]
of which 95%
was Pharmaceutical Manufacturing), and
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
(3.33 billion Chinese Renmimbi [US$469.95 million]
of which 49%
was Medicine Manufacturing).
During the year ended December of 2018, sales at
Haisco Pharmaceutical Group Co Ltd were 3.43 billion Chinese Renmimbi (US$483.84 million).
increase of 84.6%
versus 2017, when the company's sales were 1.86 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Haisco Pharmaceutical Group Co Ltd
(and since 2013, sales have increased a total of 245%).